Xenix Medical Announces FDA Clearance and Full Commercial Launch of the Riva Posterior Fixation System®
Xenix Medical today announced FDA 510(k) clearance for the Riva Posterior Fixation System and the successful completion of its alpha launch, marking the system's transition to full commercial availability.
Xēnix Medical Receives FDA Clearance of SOLACE™ Sacroiliac Fixation System with NANOACTIV™ Nanotechnology
Xēnix Medical, a surgical implant company focused on the development of novel science-based solutions for patients requiring spinal fusion surgery, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the SOLACE™️ Sacroiliac Fixation System with proprietary NANOACTIV™️ surface technology and compatibility with StealthStation® Navigation.
Xēnix Medical neoWave™ Interbody Systems Receive FDA Clearance for NANOACTIV™ Nanotechnology Surface
Xēnix Medical, a surgical implant company focused on the development of novel science-based solutions for patients requiring spinal fusion surgery, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for nanotechnology designation of its neoWave™ line of interbody fusion implants featuring proprietary NANOACTIV™ surface technology.
HT Medical Announces Name Change to Xēnix Medical as Part of Rebranding Initiative
HT Medical, a surgical implant company focused on the development of novel science-based solutions for patients requiring spinal fusion surgery, today announced that it has changed its name to Xēnix Medical as part of a rebranding initiative. The company also revealed that it has moved its corporate office to an expanded location in order to meet increasing demand for its proprietary neoWave™ interbody technology, formerly known as Ti3D®. The neoWave™ technology consists of a unique 3D-printed homogenous waveform matrix that enhances load dispersion while reducing device stiffness and, therefore, the potential for subsidence.
